| Bioactivity | L-threo-PPMP is a GlcT (UDP-Glc: Ceramide β1,1glucosyltransferase) inhibitor. L-threo-PPMP inhibits glycosphingolipid biosynthesis and induces apoptosis. L-threo-PPMP has anti-cancer activity[1]. |
| Invitro | L-threo-PPMP (0.5-20 μM) induces apoptosis in carcinoma (Colo-205; SKBR3) cells after 6 h and damaging DNA between 24 and 48 h after treatment[1]. L-threo-PPMP (1-16 μM; 48 hours) includes Caspase-3 activation in breast cancer SKBR3 cells[1]. |
| Name | L-threo-PPMP |
| CAS | 207278-87-3 |
| Formula | C29H50N2O3 |
| Molar Mass | 474.72 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Subhash Basu, et al. Apoptosis of human carcinoma cells in the presence of inhibitors of glycosphingolipid biosynthesis: I. Treatment of Colo-205 and SKBR3 cells with isomers of PDMP and PPMP. Glycoconj J. 2004;20(3):157-68. |
L-threo-PPMP
CAS: 207278-87-3 F: C29H50N2O3 W: 474.72
L-threo-PPMP is a GlcT (UDP-Glc: Ceramide β1,1glucosyltransferase) inhibitor. L-threo-PPMP inhibits glycosphingolipid b
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.